This page ranks therapeutic investment opportunities in neurodegenerative disease research by various criteria including market opportunity, pipeline strength, clinical trial activity, and mechanistic novelty. These rankings help identify the most promising investment areas in neurodegeneration therapeutics.
| Rank | Area | Active Programs | Phase 3 Programs | Investment Trend |
|---|---|---|---|---|
| 1 | Alzheimer's Disease | 180+ | 15 | High |
| 2 | Parkinson's Disease | 120+ | 10 | High |
| 3 | ALS | 100+ | 7 | Moderate-High |
| 4 | Huntington's Disease | 60+ | 4 | Moderate |
| 5 | Frontotemporal Dementia | 40+ | 3 | Moderate |
| 6 | Multiple System Atrophy | 25+ | 2 | Moderate |
| 7 | Progressive Supranuclear Palsy | 20+ | 1 | Moderate |
| 8 | Corticobasal Degeneration | 15+ | 1 | Low-Moderate |
| Rank | Indication | Estimated Market Size | Growth Rate |
|---|---|---|---|
| 1 | Alzheimer's Disease | $30B+ | 15-20%/year |
| 2 | Parkinson's Disease | $18B+ | 12-15%/year |
| 3 | ALS | $4B+ | 12-15%/year |
| 4 | Huntington's Disease | $2.5B+ | 8-10%/year |
| 5 | FTD | $2B+ | 12-15%/year |
Areas with novel mechanisms showing promising early data:
| Rank | Mechanism | Development Stage | Promise Level |
|---|---|---|---|
| 1 | Alpha-synuclein targeting | Phase 2-3 | Very High |
| 2 | Tau immunotherapy | Phase 2-3 | Very High |
| 3 | Gene therapy/AAV | Phase 1-2 | High |
| 4 | Protein clearance (autophagy) | Phase 1-2 | High |
| 5 | Neuroprotective small molecules | Phase 1-2 | Moderate-High |
Therapeutic modalities attracting capital:
| Rank | Modality | 2024-2026 Investment | Deal Count |
|---|---|---|---|
| 1 | Monoclonal antibodies | $7B+ | 100+ |
| 2 | Small molecules | $4B+ | 150+ |
| 3 | Gene therapy | $3B+ | 60+ |
| 4 | Cell therapy | $1.5B+ | 35+ |
| 5 | RNA therapeutics | $800M+ | 25+ |
The Alzheimer's disease pipeline is dominated by amyloid-beta and tau-targeting immunotherapies, with lecanemab and donanemab showing unprecedented Phase 3 efficacy[1]. This has validating the amyloid cascade hypothesis and driving continued investment in similar approaches.
Parkinson's disease and related synucleinopathies represent a major unmet need with active development across multiple mechanisms[2]:
Monogenic forms of neurodegenerative diseases (APP/PSEN mutations in AD, LRRK2/GBA in PD, SOD1/C9orf72 in ALS) offer validated targets and have attracted significant investment in precision medicine approaches[3].
Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023. ↩︎
Alpha-synuclein in Parkinson's disease. Nat Rev Dis Primers. 2019. ↩︎
Genetic forms of neurodegenerative disease. Nature. 2019. ↩︎